GHGuardant Health Inc
$167.98
$2.79
(1.63%)
Closed $167.98
$0.94
(0.56%)
After Hours
EarningsJul 29
Mkt Cap$22.27B
Vol3.46M
UnitedHealth Group Now Covers Guardant Healths Shield Blood Test for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or...
Business Wire
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheims HERNEXEOS
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic (CDx) for Boehringer Ingelheims HERNEXEOS (zongertinib tablets), the first targeted therapy for adults...
Business Wire
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid...
Business Wire
American Cancer Society Recommends Guardant Healths Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield...
Business Wire
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians...
Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardants Board of Directors approved the granting of...
Business Wire
Guardant Health (GH) Q1 2026 Earnings Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +4.60% and +8.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest GH News
ViewUnitedHealth Group Now Covers Guardant Healths Shield Blood Test for Colorectal Cancer Screening
Business Wire
GH Stock At Over 5-Year Highs – What’s The UnitedHealth Connection?
Stocktwits
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheims HERNEXEOS
Business Wire
Advertisement|Remove ads.